Introduction
There are conflicting reports of a possible association between type 1 diabetes mellitus (T1D) and epilepsy, particularly idiopathic generalised epilepsy (IGE). Two studies, 1,2 one exclusively undertaken in adults, 1 showed an increased prevalence of epilepsy in patients withT1D; in contrast a single paediatric study suggested that childhood epilepsy was no more frequently seen in children with T1D than in the general paediatric population. 3 Speculation on this possible association has focused on the role of autoimmunity and specifically antibodies to glutamic acid decarboxylase (GAD) which are elevated in many patients with T1D 4 and also in a number of neurological diseases. 5 The aim of this study was to try and confirm or refute this reported association. A review of clinical notes and investigations was carried out on children with T1D who were under follow-up in the Paediatric Diabetes Clinic at Alder Hey Children's Hospital.
Patients and methods
Data were collected on all children aged <16 years who had a diagnosis of T1D and who had attended the Paediatric Diabetes Clinic at least once in the 12 months of 2010 prior to the study. The clinic served a local (secondary) population. Data were extracted from the patients' case notes and the specific medical and nursing notes. In addition, all the patients in the Diabetic Clinic database were cross-checked with the EEG departmental database (which is under the supervision of RA) and the complete epilepsy patient database held by the epilepsy nurse specialists at the hospital. Finally, the paediatric neurologists and epilepsy nurse specialists were also asked to identify all patients who were known to have dual diagnoses of diabetes and epilepsy.
Epilepsy was diagnosed when two or more unprovoked euglycemic (a laboratory-measured blood glucose of >3.9 mmol/ L) had been reliably documented. The diagnosis of epilepsy was confirmed following review of the medical case-notes and EEG by a single paediatric neurologist (RA). All EEGs were recorded for a minimum of 30 min in wakefulness. Neuroimaging (magnetic resonance imaging [MRI] using a 1.5 T scanner) was also reviewed to provide additional information on other potential causes for the epilepsy. EEG and MRI were undertaken in our hospital.
Initially, all children reported to have experienced any 'seizure' were included in the study. Following review of all the documentation, those children with confirmed provoked and specifically hypoglycaemic seizures and Children with a known perinatal history of hypoxic-ischaemic encephalopathy, cerebrospinal fluid-confirmed diagnosis of meningitis or encephalitis or late-onset post-traumatic epilepsy were excluded.
Results
Data were analysed for 285 children (156 males and 129 females) aged less than 16 years with T1D. Of these 285, six children had a confirmed diagnosis of epilepsy, five with a probable IGE ( Table 1) .
Another child had experienced two seizures caused by hypoglycaemia (on both occasions blood levels <2 mmol/L) and was excluded. No child with diabetes had experienced any other Results: Of 285 children aged <16 years with type 1 diabetes, six also had epilepsy giving a prevalence of 21/1000. This is approximately six times greater than the prevalence of epilepsy in the general population of children in UK.
Conclusion: Epilepsy appears to occur more frequently in children with type 1 diabetes than in the general paediatric population.
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provoked seizures, including febrile seizures, prior to the diagnosis of epilepsy. Neonatal seizures had not been documented in the child With PVL (patient 4 in Table 1 ). Diabetes preceded epilepsy in five of the six patients; in the remaining patient (patient 2), diabetes was diagnosed a few months after the diagnosis of epilepsy.
In one patient there was a family history of T1D but not epilepsy; in another there was a family history of an IGE but not diabetes. One patient had a family history of both and in three there was no family history of diabetes or epilepsy.
All patients underwent a routine EEG and cerebral MRI was performed in four. The EEG was abnormal in three (one each showing generalised spike and wave activity, a grade 3 photoparoxysmal response and focal sharp and slow wave activity), normal in two and equivocal (showing brief paroxysms of generalised sharp wave activity) in one. MRI was normal in three of the four in whom it was undertaken; one showed mild PVL (this patient has a spastic diplegia; patient 4).
Five of the six patients received an anti-epileptic drug; the family of the remaining patient (patient 3) declined treatment. Five of the six patients have been seizure-free for between 6 and 18 months, including the patient not receiving an AED; patient 4 continues to experience brief focal seizures as manifest by periods of unresponsiveness, head deviation and automatisms every 6 weeks.
This gives an epilepsy prevalence of 21 per 1000 (2.1%) in this diabetic population. If only the five children with IGE are included, the prevalence is 17.5 per 1000 children (1.75%). The reported prevalence of epilepsy in a general paediatric population (<16 years) varies from approximately 3.6 (Joint Epilepsy Council document published in 2005: www.jointepilepsycouncil.org.uk/ downloads/Epilepsy%20Prevalence%20Incidence%20an-d%20Other%20Statistics.pdf [accessed August 2011]) to 5 per 1000. 6 This suggests that in our population there may be between over three and almost six-fold increase in epilepsy in children with T1D.
Discussion
The issue whether individuals with T1D are at increased risk of epilepsy because of a lowered threshold or increased susceptibility has been addressed in a very small number of studies [1] [2] [3] and with conflicting results. Our study, ascertained from a UK paediatric diabetes clinic database, has shown over a three to almost a six-fold increase in the prevalence of IGE in children with T1D. A UK study by McCorry et al. showed a four-fold increase in risk of T1D in young adults with IGE. 1 Their study, with patients accessed from an epilepsy and not diabetes clinic population, also showed that six of their seven patients with both conditions developed diabetes prior to their epilepsy. 1 Similar findings were reported from an Italian diabetic clinic with 6 of 249 patients with T1D having epilepsy (four, IGE and two idiopathic focal epilepsy); epilepsy had an onset <15 years of age in all six and prior to diabetes in one patient. 2 However, the findings of both studies are in contrast to an Australian paediatric study which showed no increased risk of IGE in their paediatric population with T1D. 3 The prevalence of active epilepsy in their diabetic population was 8.7 per 1000 compared to 5-10 per 1000 in their general population. However, this latter figure is considerably higher than the cited prevalence data of epilepsy for the general paediatric population in the UK and this difference could in part explain their finding that they found no association between T1D and epilepsy. A number of hypotheses have been postulated to explain the increased prevalence of epilepsy, and specifically IGE, in individuals with T1D. The focus seems to be an auto-immune mechanism. 5, 7, 8 It is not possible to comment on the postulated shared auto-immune pathogenesis of both T1D and IGE in our study because anti-GAD antibodies were not measured in any of our diabetic population. In addition, there may be subtle antigenic differences between epitopes recognised by anti-GAD antibodies in patients with IGE and type 1 diabetes. 8 However, it would seem appropriate to consider the possibility of a genetic component, in view of the likelihood that many of the IGEs are considered to have a genetic basis. There are clear imitations with this study, many of which have been noted previously [1] [2] [3] and which relate to the retrospective nature of the study and accurate case-ascertainment of epilepsy. These limitations could be addressed by a prospective and multicentre population study which includes techniques that maximises the accurate diagnosis of both hypoglycaemic and unprovoked (epileptic) seizures. Ideally, such a study should also use more objective biochemical (such as anti-GAD antibodies using highly specific assays) and genetic markers.
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